A Phase 2 Multicenter Single Arm Clinical Trial of ABX-EGF Monotherapy in Subjects With Metastatic Colorectal Cancer Whose Tumors Express Low or Negative EGFr Levels of Immunohistochemistry Following Treatment With Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy
Interventional
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
MD
Study Director
Amgen
United States: Food and Drug Administration
20030250
NCT00089635
August 2004
December 2008
Name | Location |
---|---|
Research Site | Alabaster, Alabama |
Research Site | Mesa, Arizona |
Research Site | Bentonville, Arkansas |
Research Site | Anaheim, California |
Research Site | Boulder, Colorado |
Research Site | Danbury, Connecticut |
Research Site | Boca Raton, Florida |
Research Site | Albany, Georgia |
Research Site | Boise, Idaho |
Research Site | Arlington Heights, Illinois |
Research Site | Bloomington, Indiana |
Research Site | Hays, Kansas |
Research Site | Ashland, Kentucky |
Research Site | Baltimore, Maryland |
Research Site | Battle Kreek, Michigan |
Research Site | Alexandria, Minnesota |
Research Site | Branson, Missouri |
Research Site | Billings, Montana |
Research Site | Grand Island, Nebraska |
Research Site | Las Vegas, Nevada |
Research Site | Belleville, New Jersey |
Research Site | Albuquerque, New Mexico |
Research Site | Albany, New York |
Research Site | Asheville, North Carolina |
Research Site | Akron, Ohio |
Research Site | Enid, Oklahoma |
Research Site | Bend, Oregon |
Research Site | Allentown, Pennsylvania |
Research Site | Charleston, South Carolina |
Research Site | Chattanooga, Tennessee |
Research Site | Abilene, Texas |
Research Site | Ivins, Utah |
Research Site | Abington, Virginia |
Research Site | Auburn, Washington |
Research Site | Appleton, Wisconsin |